Clinical trials: CART Cells
Metastatic Colorectal Cancer
EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.
- Trial name
- EGFRCART (NCT03542799)
- Testing
- EGFR IL12 CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Lymphoma Non-Hodgkin, Agressive Lymphoma
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase 1, first-in-human, open-label, multicenter study of CC-97540, CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Conditions
- Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)
- Trial name
- NCT04231747
- Testing
- CC-97540
- Where
- 14 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Evaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients
- Trial name
- NCT07169500
- Testing
- CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, AIDS Related, HIV Infections
A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
No standard regimen currently exists for the treatment of AIDS-related lymphoma. Based on the encouraging NCI results with DA-EPOCH, the US AIDS Malignancy Consortium is currently administering a phase II randomized protocol…
- Trial name
- CATCH (NCT00799136)
- Testing
- R-EPOCH and cART
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Vaccine Immunity in CAR-T Cell Therapy Recipients
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
The goal of this observational study is to learn about vaccine immunity in patients with B-cell malignancies treated by chimeric antigen receptor T-cell therapies (CAR-T).
- Trial name
- IMCAR (NCT06333275)
- Testing
- Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
B-cell Lymphoma
PD1-CD19-CART in Patients With r/r B-cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.
- Trial name
- NCT04213469
- Testing
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
CART Therapy
CAR-T Cell Therapy in Patients With Hematological Malignancies
The prognosis of relapsed or refractory lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) is poor with conventional treatment with complete response rates around 25-30% with a median progression-free…
- Trial name
- NCT05390671
- Where
- Spain
- Volunteers
- 260 people
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07109518
- Testing
- uCD7 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
This phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06236139
- Testing
- Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Multiple Myeloma
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM).
- Trial name
- NCT04142619
- Testing
- UCARTCS1A
- Where
- 8 sites in United States
- Volunteers
- 11 people
- Sponsor
- Cellectis S.A.
High-risk R/R LBCL
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk…
- Trial name
- CAR-T+ASCT (NCT07538635)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Multiple Myeloma
Efficacy and Safety Evaluation of PD1-BCMA-CART
This trial aims to evaluate the safety and efficacy of PD1-BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05308875
- Testing
- PD1-BCMA-CART
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Bioray Laboratories
Non-hodgkin Lymphoma, Refractory Lymphoma
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
- Conditions
- Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
- Trial name
- NCT06875063
- Testing
- GB5005 CART
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
NK T-Cell Lymphoma, CART Therapy
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural…
- Conditions
- NK T-Cell Lymphoma, CART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- Trial name
- NCT06732492
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Relapsed/Refractory Multiple Myeloma (MM)
Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.
- Trial name
- CART-BCMA (NCT07458659)
- Testing
- Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- Thailand
- Volunteers
- 3 people
- Sponsor
- Chulalongkorn University
Recurrent Glioblastoma, CD147 Positive
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
- Trial name
- NCT04045847
- Testing
- CD147-CART
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae